The main objective of this study is to analyze the survival of a cohort of patients admitted
for acute decompensation of pulmonary arterial hypertension or postembolic pulmonary
hypertension and to establish the prognostic value of biomarkers.
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.
Searching Both is inclusive of interventional and observational studies.
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.
Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.
Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.
The person who is responsible for the scientific and technical direction of the entire clinical study.
Category of organization(s) involved as sponsor (and collaborator) supporting the trial.
The disease, disorder, syndrome, illness, or injury that is being studied.
It is planned to include 150 patients over a two-year period. The primary endpoint is a
composite endpoint including death, circulatory assistance or emergency transplantation
within 90 days following admission to intensive care unit. Patients will be treated according
to the usual practice. A biobank will be created from blood samples taken at admission, days
3 and days 7. Prognostic value of pre-selected biomarkers will be analyzed and a proteomic
analysis will be performed in order to identify new biomarkers. The prognostic value of these
new biological parameters will be compared to the usual monitoring parameters that will be
collected during follow-up (clinical, echocardiographic and haemodynamic parameters). In a
second step, it will establish, using a dynamic model, the best combinations of parameters
allowing to best assessment of prognosis of patients suffering from PH and hospitalized for
acute right ventricular failure.
Other: Patients with Pulmonary arterial hypertension
Pulmonary arterial hypertension or non-operable chronic thromboembolic pulmonary hypertension established by right cardiac catheterization prior to inclusion in the study
Other: - A biobank will be created from blood samples taken at admission, days 3 and days 7
A biobank will be created from the blood samples taken on admission, days 3 and 7 of admission. The prognostic value of the preselected biomarkers will be analyzed and a proteomic analysis will be performed to identify new biomarkers. The prognostic value of these new biological parameters will be compared to the usual surveillance parameters that will be collected during the follow-up (clinical, echocardiographic and hemodynamic parameters)
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Le Kremlin-Bicêtre, , 94270
SAVALE Laurent, PHD
01 45 21 79 74